Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 4/20 | 0.70 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.70 |
| ▸ | ADRA2C | P18825 | 4/20 | 0.70 |
| ▸ | PLAU | P00749 | 4/20 | 0.70 |
| ▸ | NOS3 | P29474 | 3/20 | 0.54 |
| ▸ | NOS1 | P29475 | 3/20 | 0.54 |
| ▸ | NOS2 | P35228 | 3/20 | 0.54 |
| ▸ | MAOA | P21397 | 2/20 | 0.44 |
| ▸ | MAOB | P27338 | 2/20 | 0.44 |
| ▸ | PI4KA | P42356 | 1/20 | 0.38 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.38 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.38 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1703431 | 1.00 | ADRA2A (0.70) | ADRA2AADRA2BADRA2CPLAUNOS3 | |
| SCHEMBL2226462 | 0.83 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CPLAUNOS3 | |
| SCHEMBL4316417 | 0.83 | ADRA2A (0.63) | ADRA2AADRA2BADRA2CPLAUNOS3 | |
| SCHEMBL11304297 | 0.76 | ADRA2A (0.66) | ADRA2AADRA2BADRA2CPLAUNOS3 | |
| Sulfuric Acid SCHEMBL11274223 | 0.75 | ADRA2A (0.81) | ADRA2AADRA2BADRA2CPLAUNOS3 | |
| SCHEMBL9632322 | 0.73 | ADRA2A (0.61) | ADRA2AADRA2BADRA2CPLAUNOS3 | |
| SCHEMBL10499203 | 0.72 | ADRA2A (0.97) | ADRA2AADRA2BADRA2CPLAUNOS3 | |
| SCHEMBL10499209 | 0.72 | ADRA2A (0.97) | ADRA2AADRA2BADRA2CPLAUNOS3 | |
| SCHEMBL206947 | 0.71 | ADRA2A (0.59) | ADRA2AADRA2BADRA2CPLAUNOS3 | |
| SCHEMBL30201747 | 0.71 | ADRA2A (0.59) | ADRA2AADRA2BADRA2CPLAUNOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009086835-A1 | NOVEL CYANOGUANIDINES | TOPOTARGET A/S (DK) | 2009-07-16 | — | — | WO | disclosed |
| US-6518309-B1 | Poly-substituted isothiouronium salts as microbiocida surface active antifouling agents | RHOCRAFT RESEARCH AND DEVELOPMENT LTD. (CA) | 2003-02-11 | — | — | US | disclosed |
| US-20020177627-A1 | Microbiocidal properties of poly-substituted guanidinium salts | RHOCRAFT RESEARCH DEVELOPMENT, LTD. | 2002-11-28 | — | — | US | disclosed |
| WO-2001079359-A2 | GUANIDINIUM AND ISOTHIOURONIUM COMPOUNDS AND METHODS FOR THEIR USE | UNIVERSITY OF VICTORIA INNOVATION AND DEVELOPMENT CORPORATION (CA) | 2001-10-25 | — | — | WO | disclosed |
| EP-0984936-A1 | CYANOGUANIDINES AS CELL PROLIFERATION INHIBITORS | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LOVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB) (DK) | 2000-03-15 | — | — | EP | disclosed |
| WO-1998054142-A1 | CYANOGUANIDINES AS CELL PROLIFERATION INHIBITORS | Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) (DK) | 1998-12-03 | — | — | WO | disclosed |
| WO-1998054141-A1 | CYANOGUANIDINES AS CELL PROLIFERATION INHIBITORS | Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) (DK) | 1998-12-03 | — | — | WO | disclosed |
| US-4431802-A | N-Heterocyclyl-N-cyano-N-(heterocyclythioalkyl)-guanidines | G. D. SEARLE & CO. (US) | 1984-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020177627-A1 | Microbiocidal properties of poly-substituted guanidinium salts | MSR1, FPR3, ARG1 | ADRA2A 2439/4885ADRA2B 1373/4885ADRA2C 1936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.